- Home
- CYTK
as 05-08-2025 4:00pm EST
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 5.6B | IPO Year: | 2004 |
| Target Price: | $77.33 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $31.67 - $68.44 | Next Earning Date: | 05-06-2025 |
| Revenue: | $19,218,000 | Revenue Growth: | 412.21% |
| Revenue Growth (this year): | 55.84% | Revenue Growth (next year): | 646.96% |
Stock Insider Trading Activity of Cytokinetics Incorporated (CYTK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | CYTK | EVP Research & Development | May 6 '25 | Sell | $35.01 | 2,000 | $70,020.00 | 140,255 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | May 5 '25 | Sell | $36.68 | 4,002 | $146,793.36 | 60,687 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Apr 22 '25 | Sell | $38.11 | 2,000 | $76,220.00 | 140,255 | |
| WIERENGA WENDALL | CYTK | Director | Apr 21 '25 | Sell | $38.46 | 20,000 | $769,200.00 | 24,848 | |
| HENDERSON JOHN T | CYTK | Director | Apr 15 '25 | Sell | $38.66 | 3,190 | $123,325.40 | 66,348 | |
| Blum Robert I | CYTK | President & CEO | Apr 10 '25 | Sell | $36.77 | 5,000 | $183,850.00 | 422,629 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Apr 8 '25 | Sell | $36.18 | 2,000 | $72,360.00 | 140,255 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Apr 7 '25 | Sell | $35.78 | 2,886 | $103,261.08 | 60,687 | |
| Harrington Robert Arthur | CYTK | Director | Apr 3 '25 | Sell | $39.43 | 450 | $17,743.50 | 14,658 | |
| Blum Robert I | CYTK | President & CEO | Mar 31 '25 | Sell | $40.75 | 15,000 | $611,250.00 | 422,629 |
Latest Cytokinetics Incorporated News
CYTK Breaking Stock News: Dive into CYTK Ticker-Specific Updates for Smart Investing
MT Newswires
8 hours ago
B. Riley Adjusts Cytokinetics Price Target to $74 From $88, Maintains Buy Rating
Simply Wall St.
11 hours ago
Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
a day ago
Cytokinetics to Hold Annual Meeting of Stockholders
Zacks
a day ago
Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended
MT Newswires
a day ago
RBC Trims Price Target on Cytokinetics to $80 From $82, Keeps Outperform, Speculative Risk
GuruFocus.com
2 days ago
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges
Argus Research
2 days ago
CYTK: Lowering target price to $27.00
MT Newswires
2 days ago
Cytokinetics Q1 Net Loss Widens, Revenue Rises
Compare CYTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYTK Cytokinetics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.